The chief scientific officer of Sangamo Therapeutics discussed the company’s AAV capsid evolution research.
Jason Fontenot, PhD
Advertisement
Senior vice president and chief scientific officer, Sangamo Therapeutics
Articles by Jason Fontenot, PhD
The chief scientific officer of Sangamo Therapeutics discussed data from 2 of the company’s programs that were presented at ASGCT’s 2023 conference.
The chief scientific officer of Sangamo Therapeutics discussed the first-in-human STEADFAST trial.
Advertisement
Latest Updated Articles
Jason Fontenot, PhD, on Reducing the Need for Immunosuppression in Renal TransplantationPublished: May 25th 2022 | Updated:
